23 Jul 2018 | 3:59 AM

News

COMPANYNEWS
Zydus Hospira JV gets EIR for its manufacturing facility at Ahmedabad
  |
Published on 07-12-2018
Cadila Healthcare said that the manufacturing facility of Zydus Hopsira Oncology a 50:50 joint venture company between Zydus Cadila and Hospira Inc. USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA.


“Zydus Hopsira Oncology a 50:50 joint venture company between Zydus Cadila and Hospira Inc. USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA. which concluded that the inspection is "closed" and states that the inspection classification of this facility is `Voluntary Action Indicated` (VAI)” the company said in a filing to the Bombay Stock Exchange.


The manufacturing plant had completed the USFDA audit from 5 to 12 April 2018.


Meanwhile shares of the company were trading at Rs 367.10 apiece down 1.18 per cent from the previous close at 15:15 hours on BSE.